TIPS for Complicated Portal Hypertension Related to Porto-Sinusoidal Vascular Disease
NCT07163689
Digestive System Diseases, Esophageal Diseases
Amiens, Picardie, France
View Trial DetailsNCT Number: NCT06970509
Endoscopic esophageal variceal ligation combined with gastric variceal embolization using tissue glue is currently the first-choice method for preventing rebleeding in patients with cirrhosis and portal hypertension. However, the rebleeding rate remains relatively high. Factors such as extra-luminal vascular bundles in the esophagus and stomach walls, and portosystemic shunts significantly affect the therapeutic outcomes. Therefore, there is an urgent need to develop an individualized treatment model for esophagogastric varices based on the anatomical and hemodynamic characteristics of the varices, to stratify patient risks and provide tailored treatment options.
Before the treatment of esophagogastric varices, the vascular characteristics of esophagogastric varices are assessed based on imaging data such as portal venous CT and ultrasound, as well as clinical information. Risk factors influencing bleeding from esophagogastric varices are explored, and an endoscopic and interventional variceal stratification and treatment model is constructed to provide patients with personalized options for endoscopic or interventional therapy.
During the treatment of esophagogastric varices, precise endovascular embolization of the source branch vessels of esophagogastric varices is performed based on hemodynamic models. The safety and efficacy of this treatment strategy are verified through randomized controlled clinical trials.
After the treatment of esophagogastric varices, the feasibility of reducing the risk of rebleeding in patients with poor endoscopic outcomes is examined by using drugs that lower portal venous pressure, such as carvedilol or novel oral anticoagulants. Factors influencing recompensation and reversal of portal hypertension are also clarified.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 year
Gastrointestinal bleeding within 1 year
Time frame: 6 months, 3 years, and 5 years
Gastrointestinal bleeding within 6 months, 3 years, and 5 years
Time frame: 6 months, 1 year, 3 years, and 5 years
The occurrence of events such as ascites progression, overt jaundice, changes in portal vein thrombosis, hepatocellular carcinoma, liver transplantation, or survival and death within 6 months, 1 year, 3 years, and 5 years.
Contact information is provided by the study sponsor or research team.
Yiting Wang, Ph.D.
CONTACT
xiaoquan huang, M.D.
CONTACT
Shanghai Zhongshan Hospital
Other
Improve the Strategies of Endoscopic and Interventional Treatment of Gastroesophageal Hemorrhage in Portal Hypertension: Novel Strategies for Diagnosis, Treatment and Prognostic Assessment System of Cirrhotic Portal Hypertension
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07163689
Digestive System Diseases, Esophageal Diseases
Amiens, Picardie, France
View Trial DetailsNCT07587671
Brain Diseases, Brain Diseases, Metabolic
Chengdu, China
View Trial DetailsNCT07571876
Chronic Liver Disease (CLD), Digestive System Diseases
View Trial DetailsNCT07502729
Digestive System Diseases, Esophageal Diseases
View Trial Details